Kawasaki Disease and Toxic Shock Syndrome—At Last the Etiology is Clear?

  • Nigel Curtis
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 549)


The Gram-positive bacteria S. aureus and group A streptococci (GAS) are common causes of colonization or infection. Diseases associated with S. aureus infection range from superficial skin infections, such as impetigo and furuncles, at one end of the spectrum to pyogenic abscesses, endocarditis, bone and joint infection, and toxic shock syndrome (TSS) at the other extreme. Similarly, infection with GAS ranges from pharyngitis to streptococcal toxic shock-like syndrome (TSLS) (Cunningham, 2000).


Kawasaki Disease Kawasaki Disease Patient Versus Beta Kawasaki Syndrome Streptococcal Toxic Shock Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abe, J., Kotzin, B.L., Jujo, K., Melish, M.E., Glode, M.P., Kohsaka, T. et al. (1992). Selective expansion of T cells expressing T-cell receptor variable regions V beta 2 and V beta 8 in Kawasaki disease. Proc. Natl. Acad. Sci. USA 89(9), 4066–4070.PubMedCrossRefGoogle Scholar
  2. Abe, J., Kotzin, B.L., Meissner, C., Melish, M.E., Takahashi, M., Fulton, D. et al. (1993). Characterization of T cell repertoire changes in acute Kawasaki disease. J. Exp. Med. 177(3), 791–796.PubMedCrossRefGoogle Scholar
  3. Biezeveld, M.H., Kuipers, I.M., Geissler, J., Lam, J., Ottenkamp, J.J., Hack, C.E. et al. (2003). Association of mannose-binding lectin genotype with cardiovascular abnormalities in Kawasaki disease. Lancet 361(9365), 1268–1270.PubMedCrossRefGoogle Scholar
  4. Brogan, P.A., Bose, A., Burgner, D., Shingadia, D., Tulloh, R., Michie, C. et al. (2002). Kawasaki disease: An evidence based approach to diagnosis, treatment, and proposals for future research. Arch. Dis. Child. 86(4), 286–290.PubMedCrossRefGoogle Scholar
  5. Brogan, P.A., Shah, V., Bagga, A., Klein, N., and Dillon, M.J. (2003). T cell Vbeta repertoires in childhood vasculitides. Clin. Exp. Immunol. 131(3), 517–527.PubMedCrossRefGoogle Scholar
  6. Choi, I.H., Chwae, Y.J., Shim, W.S., Kim, D.S., Kwon, D.H., Kim, J.D. et al. (1997). Clonal expansion of CD8 + T cells in Kawasaki disease. J. Immunol. 159(1), 481–486.PubMedGoogle Scholar
  7. Choi, Y., Lafferty, J.A., Clements, J.R., Todd, J.K., Gelfand, E.W., Kappler, J. et al. (1990). Selective expansion of T cells expressing V beta 2 in toxic shock syndrome. J. Exp. Med. 172(3), 981–984.PubMedCrossRefGoogle Scholar
  8. Cunningham, M.W. (2000). Pathogenesis of group A streptococcal infections. Clin. Microbiol. Rev. 13(3), 470–511.PubMedCrossRefGoogle Scholar
  9. Curtis, N., Chan, B., and Levin, M. (1994). Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 343(8892), 299.PubMedCrossRefGoogle Scholar
  10. Curtis, N. and Levin, M. (1998). Kawasaki disease thirty years on. Curr. Opin. Pediatr. 10(1), 24–33.PubMedCrossRefGoogle Scholar
  11. Curtis, N., Zheng, R., Lamb, J.R., and Levin, M. (1995). Evidence for a superantigen mediated process in Kawasaki disease. Arch. Dis. Child. 72(4), 308–311.PubMedCrossRefGoogle Scholar
  12. Darenberg, J., Ihendyane, N., Sjolin, J., Aufwerber, E., Haidl, S., Follin, P. et al. (2003). Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: A European randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. 37(3), 333–340.PubMedCrossRefGoogle Scholar
  13. Davies, H.D., Kirk, V., Jadavji, T., and Kotzin, B.L. (1996). Simultaneous presentation of Kawasaki disease and toxic shock syndrome in an adolescent male. Pediatr. Infect. Dis. J. 15(12), 1136–1138.PubMedCrossRefGoogle Scholar
  14. De Inocencio, J. and Hirsch, R. (1995). Evidence for superantigen mediated process in Kawasaki disease. Arch. Dis. Child. 73(3), 275–276.Google Scholar
  15. Duong, T.T., Silverman, E.D., Bissessar, M.V., and Yeung, R.S. (2003). Superantigenic activity is responsible for induction of coronary arteritis in mice: An animal model of Kawasaki disease. Int. Immunol. 15(1), 79–89.PubMedCrossRefGoogle Scholar
  16. Fraser, J., Arcus, V., Kong, P., Baker, E., and Proft, T. (2000). Superantigens—powerful modifiers of the immune system. Mol. Med. Today 6(3), 125–132.PubMedCrossRefGoogle Scholar
  17. Herbert, S., Barry, P., and Novick, R.P. (2001). Subinhibitory clindamycin differentially inhibits transcription of exoprotein genes in Staphylococcus aureus. Infect. Immun. 69(5), 2996–3003.PubMedCrossRefGoogle Scholar
  18. Kaul, R., McGeer, A., Norrby-Teglund, A., Kotb, M., Schwartz, B., O’Rourke, K. et al. (1999). Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome—a comparative observational study. The Canadian Streptococcal Study Group. Clin. Infect. Dis. 28(4), 800–807.PubMedCrossRefGoogle Scholar
  19. Kotzin, B.L., Leung, D.Y., Kappler, J., and Marrack, P. (1993). Superantigens and their potential role in human disease. Adv. Immunol. 54, 99–166.PubMedCrossRefGoogle Scholar
  20. Leung, D.Y., Giorno, R.C., Kazemi, L.V., Flynn, P.A., and Busse, J.B. (1995). Evidence for superantigen involvement in cardiovascular injury due to Kawasaki syndrome. J. Immunol. 155(10), 5018–5021.PubMedGoogle Scholar
  21. Leung, D.Y., Meissner, H.C., Fulton, D.R., Murray, D.L., Kotzin, B.L., and Schlievert, P.M. (1993). Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 342(8884), 1385–1388.PubMedCrossRefGoogle Scholar
  22. Leung, D.Y., Meissner, H.C., Shulman, S.T., Mason, W.H., Gerber, M.A., Glode, M.P. et al. (2002). Prevalence of superantigen-secreting bacteria in patients with Kawasaki disease. J. Pediatr. 140(6), 742–746.PubMedCrossRefGoogle Scholar
  23. Leung, D.Y., Sullivan, K.E., Brown-Whitehorn, T.F., Fehringer, A.P., Allen, S., Finkel, T.H. et al. (1997). Association of toxic shock syndrome toxin-secreting and exfoliative toxin-secreting Staphylococcus aureus with Kawasaki syndrome complicated by coronary artery disease. Pediatr. Res. 42(3), 268–272.PubMedCrossRefGoogle Scholar
  24. Levin, M., Tizard, E.J., and Dillon, M.J. (1991). Kawasaki disease: Recent advances. Arch. Dis. Child. 66(12), 1369–1372.PubMedCrossRefGoogle Scholar
  25. Llewelyn, M. and Cohen, J. (2002). Superantigens: Microbial agents that corrupt immunity. Lancet Infect. Dis. 2(3), 156–162.PubMedCrossRefGoogle Scholar
  26. Mancia, L., Wahlstrom, J., Schiller, B., Chini, L., Elinder, G., D’Argenio, P. et al. (1998). Characterization of the T-cell receptor V-beta repertoire in Kawasaki disease. Scand. J. Immunol. 48(4), 443–449.PubMedCrossRefGoogle Scholar
  27. Marrack, P. and Kappler, J. (1990). The staphylococcal enterotoxins and their relatives. Science 248(4959), 1066.PubMedGoogle Scholar
  28. Masuda, K., Takei, S., Nomura, Y., Imanaka, H., Sameshima, K., and Yoshinaga, M. (1998). Transient low T cell response to streptococcal pyrogenic exotoxin-C in patients with Kawasaki disease. Pediatr. Res. 44(1), 27–31.PubMedCrossRefGoogle Scholar
  29. Matsuda, Y., Kato, H., Yamada, R., Okano, H., Ohta, H., Imanishi, K. et al. (2003). Early and definitive diagnosis of toxic shock syndrome by detection of marked expansion of T-cell-receptor VBeta2-positive T cells. Emerg. Infect. Dis. 9(3), 387–389.PubMedCrossRefGoogle Scholar
  30. Meissner, H.C. and Leung, D.Y. (2000). Superantigens, conventional antigens and the etiology of Kawasaki syndrome. Pediatr. Infect. Dis. J. 19(2), 91–94.PubMedCrossRefGoogle Scholar
  31. Melish, M.E. (1992). Kawasaki syndrome: A 1992 update. Pediatr. Dermatol. 9(4), 335–337.PubMedCrossRefGoogle Scholar
  32. Nakano, T., Hiramatsu, K., Kishi, K., Hirata, N., Kadota, J., and Nasu, M. (2003). Clindamycin modulates inflammatory-cytokine induction in lipopolysaccharide-stimulated mouse peritoneal macrophages. Antimicrob. Agents Chemother. 47(1), 363–367.PubMedCrossRefGoogle Scholar
  33. Nomura, Y., Masuda, K., Shinkoda, Y., Sameshima, K., Oku, S., Yoshinaga, M. et al. (1998). Twenty-five types of T-cell receptor Vbeta family repertoire in patients with Kawasaki syndrome. Eur. J. Pediatr. 157(12), 981–986.PubMedCrossRefGoogle Scholar
  34. Nomura, Y., Yoshinaga, M., Masuda, K., Takei, S., and Miyata, K. (2002). Maternal antibody against toxic shock syndrome toxin-1 may protect infants younger than 6 months of age from developing Kawasaki syndrome. J Infect. Dis. 185(11), 1677–1680.PubMedCrossRefGoogle Scholar
  35. Ouchi, K., Suzuki, Y., Shirakawa, T., and Kishi, F. (2003). Polymorphism of SLC11A1 (formerly NRAMP1) gene confers susceptibility to Kawasaki disease. J. Infect. Dis. 187(2), 326–329.PubMedCrossRefGoogle Scholar
  36. Pietra, B.A., De Inocencio, J., Giannini, E.H., and Hirsch, R. (1994). TCR V beta family repertoire and T cell activation markers in Kawasaki disease. J. Immunol. 153(4), 1881–1888.PubMedGoogle Scholar
  37. Quasney, M.W., Bronstein, D.E., Cantor, R.M., Zhang, Q., Stroupe, C., Shike, H. et al. (2001). Increased frequency of alleles associated with elevated tumor necrosis factor-alpha levels in children with Kawasaki disease. Pediatr. Res. 49(5), 686–690.PubMedCrossRefGoogle Scholar
  38. Reichardt, P., Lehmann, I., Sierig, G., and Borte, M. (2002). Analysis of T-cell receptor V-beta 2 in peripheral blood lymphocytes as a diagnostic marker for Kawasaki disease. Infection 30(6), 360–364.PubMedCrossRefGoogle Scholar
  39. Rowley, A.H. (1999). The etiology of Kawasaki disease: Superantigen or conventional antigen? Pediatr. Infect. Dis. J. 18(1), 69–70.PubMedCrossRefGoogle Scholar
  40. Rowley, A.H. and Shulman, S.T. (1999). Kawasaki syndrome. Pediatr. Clin. North Am. 46(2), 313–329.PubMedCrossRefGoogle Scholar
  41. Sakaguchi, M., Kato, H., Nishiyori, A., Sagawa, K., and Itoh, K. (1995). Characterization of CD4+ T helper cells in patients with Kawasaki disease (KD): Preferential production of tumour necrosis factor-alpha (TNF-alpha) by V beta 2-or V beta 8-CD4+ T helper cells. Clin. Exp. Immunol. 99(2), 276–282.PubMedCrossRefGoogle Scholar
  42. Sriskandan, S., McKee, A., Hall, L., and Cohen, J. (1997). Comparative effects of clindamycin and ampicillin on superantigenic activity of Streptococcus pyogenes. J. Antimicrob. Chemother. 40(2), 275–277.PubMedCrossRefGoogle Scholar
  43. Stevens, D.L. (2002). Streptococcal toxic shock syndrome. Clin. Microbiol. Infect. 8(3), 133–136.PubMedCrossRefGoogle Scholar
  44. Terai, M., Miwa, K., Williams, T., Kabat, W., Fukuyama, M., Okajima, Y. et al. (1995). The absence of evidence of staphylococcal toxin involvement in the pathogenesis of Kawasaki disease. J. Infect. Dis. 172(2), 558–561.PubMedCrossRefGoogle Scholar
  45. Todd, J.K. (1988). Toxic shock syndrome. Clin. Microbiol. Rev. 1(4), 432–446.PubMedGoogle Scholar
  46. Todome, Y., Ohkuni, H., Mizuse, M., Okibayashi, F., Ohtani, N., Suzuki, H. et al. (1995). Superantigenic exotoxin production by isolates of Staphylococcus aureus from the Kawasaki syndrome patients and age-matched control children. J. Med. Microbiol. 42(2), 91–95.PubMedCrossRefGoogle Scholar
  47. Yamashiro, Y., Nagata, S., Oguchi, S., and Shimizu, T. (1996). Selective increase of V beta 2+ T cells in the small intestinal mucosa in Kawasaki disease. Pediatr. Res. 39(2), 264–266.PubMedCrossRefGoogle Scholar
  48. Yoshioka, T., Matsutani, T., Iwagami, S., Toyosaki-Maeda, T., Yutsudo, T., Tsuruta, Y. et al. (1999). Polyclonal expansion of TCRBV2-and TCRBVö-bearing T cells in patients with Kawasaki disease. Immunology 96(3), 465–472.PubMedCrossRefGoogle Scholar
  49. Yoshioka, T., Matsutani, T., Toyosaki-Maeda, T., Suzuki, H., Uemura, S., Suzuki, R. et al. (2003). Relation of streptococcal pyrogenic exotoxin C as a causative superantigen for Kawasaki disease. Pediatr. Res. 53(3), 403–110.PubMedCrossRefGoogle Scholar

Copyright information

© Science+Business Media New York 2004

Authors and Affiliations

  • Nigel Curtis

There are no affiliations available

Personalised recommendations